A leading national securities law firm is investigating potential claims against Replimune Group, Inc. following a significant stock drop after the company received a Complete Response Letter from the FDA regarding its Biologics License Application for advanced melanoma treatment.
Replimune’s stock plummeted over 73% on July 22, 2025, amid concerns over the FDA’s decision to deny approval of its application in its present form. The company had announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), which stated that the IGNYTE trial was not considered adequate to provide substantial evidence of effectiveness.
Faruqi & Faruqui, LLP is representing investors who suffered significant losses in Replimune stock or options. The law firm has recovered hundreds of millions of dollars for investors since its founding in 1995 and encourages those affected to contact them directly to discuss their options.
Investors can reach out to the law firm’s Securities Litigation Partner James (Josh) Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) to learn more about their legal rights and potential claims against Replimune.
Source: https://www.newsfilecorp.com/release/261173/SHAREHOLDER-NOTICE-Faruqi-Faruqi-LLP-Investigates-Claims-on-Behalf-of-Investors-of-Replimune